JNJ
Johnson & Johnson News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 14,
"returned": 10,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "82171c85-3ba5-44b1-a3ff-f10b3ad077c4",
"title": "HDV: Less Volatile Dividend ETF With Diverse Holdings (NYSEARCA:HDV)",
"description": "iShares Core High Dividend ETF offers stability in dividend income. Read why HDV remains a solid choice for investors looking to prioritize income.",
"keywords": "",
"snippet": "Jacob Wackerhausen\n\nOverview\n\nI previously covered iShares Core High Dividend ETF (NYSEARCA:HDV) and made the mistake of giving it a Hold rating. When I initial...",
"url": "https://seekingalpha.com/article/4687890-hdv-less-volatile-dividend-etf-diverse-holdings",
"image_url": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1589870250/image_1589870250.jpg?io=getty-c-w1536",
"language": "en",
"published_at": "2024-05-01T09:35:20.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "JNJ",
"name": "Johnson & Johnson",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 15.24855,
"sentiment_score": 0.55265,
"highlights": [
{
"highlight": "For example, I recently wrote an analysis on <em>Johnson</em> & <em>Johnson</em> (JNJ) where I discussed that they have ongoing lawsuits related to cough syrup recalls as well as a $700M settlement for talcum powder.\n\nSimilarly, energy companies also remain vulnerable to commodity price shifts.",
"sentiment": 0.1779,
"highlighted_in": "main_text"
},
{
"highlight": "Here are the top ten holdings:\n\nTicker Name Sector Weight (XOM) EXXON MOBIL CORP Energy 8.56% (CVX) CHEVRON CORP Energy 6.86% (VZ) VERIZON COMMUNICATIONS INC Communication 5.69% (JNJ) <em>JOHNSON</em> & <em>JOHNSON</em> Health Care 5.35% (ABBV) ABBVIE INC Health Care 4.95% (PM) PHILIP MORRIS INTERNATIONAL INC Consumer Staples 4.29% (MRK) MERCK & CO INC Health Care 4.16%",
"sentiment": 0.9274,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "bc0d4d6b-2426-4c20-96c0-15fd515cfd76",
"title": "3 No-Brainer Stocks to Buy With $200 Right Now",
"description": "You don't need a mountain of cash to grow your wealth on Wall Street.",
"keywords": "",
"snippet": "Investors have been taken for quite the ride over the previous four years. All three of Wall Street's major stocks indexes – the Dow Jones Industrial Average,...",
"url": "https://finance.yahoo.com/news/3-no-brainer-stocks-buy-092100906.html",
"image_url": "https://s.yimg.com/ny/api/res/1.2/u8aeO.nlh37T3tbD.ohPmA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/34a304bd6a35903ee524e4df474db002",
"language": "en",
"published_at": "2024-05-01T09:21:00.000000Z",
"source": "finance.yahoo.com",
"relevance_score": null,
"entities": [
{
"symbol": "JNJ",
"name": "Johnson & Johnson",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 43.9507,
"sentiment_score": 0.14125,
"highlights": [
{
"highlight": "<em>Johnson</em> & <em>Johnson</em>\n\nThe third no-brainer stock that makes for a surefire buy with $200 right now is none other than healthcare juggernaut <em>Johnson</em> & <em>Johnson</em> (<em>NYSE</em>: <em>JNJ</em>), which is commonly known as \"J&J.\"\n\n<em>Johnson</em> & <em>Johnson</em> has vastly underperformed the major stock indexes over the past 16 months, with litigation overhang being the primary culprit.",
"sentiment": 0.0516,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Johnson</em> & <em>Johnson</em> makes this exclusive list. It's one of only two publicly traded companies to be anointed with Standard & Poor's (S&P's) highest credit rating (AAA). S&P has no doubt that J&J can service its outstanding debt and cover any settlement liabilities it may face.",
"sentiment": -0.1027,
"highlighted_in": "main_text"
},
{
"highlight": "What makes <em>Johnson</em> & <em>Johnson</em> such a great company is that both of its operating segments are perfectly positioned for long-term success. It's been shifting its focus to pharmaceuticals for years, because novel drugs provide strong pricing power and juicy margins.",
"sentiment": 0.9559,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Johnson</em> & <em>Johnson</em> is also one of the largest medical-device makers. An aging global population should steadily improve demand for the company's medical technology solutions and improve its pricing power over time.\n\nAnother catalyst that shouldn't be overlooked is Johnson & Johnson's management team.",
"sentiment": 0.721,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Johnson</em> & <em>Johnson</em> stock is historically cheap at just 13 times forward-year consensus earnings.\n\nShould you invest $1,000 in Enterprise Products Partners right now?",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "The Motley Fool recommends Enterprise Products Partners and <em>Johnson</em> & <em>Johnson</em>. The Motley Fool has a disclosure policy.\n\n3 No-Brainer Stocks to Buy With $200 Right Now was originally published by The Motley Fool",
"sentiment": -0.7783,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "360e99ec-1ecd-43c4-a86a-0d25688558b6",
"title": "Portefeuille d'actions de MrDividende p.44",
"description": "Discussion de 1089 messages initiée par MrDividende en 2019 et mise à jour en 2024. Page 44 sur 44.",
"keywords": "action, dividende, portefeuille",
"snippet": "BILAN DU PORTEFEUILLE JANVIER 2024 (71 ÈME MOIS DE REPORTING)\n\n\n\nLe mois de Janvier a été relativement calme sur les marchés, le MSCI World affichant un gai...",
"url": "https://www.investisseurs-heureux.fr/t22362-44#p588837",
"image_url": "https://www.investisseurs-heureux.fr/images/investir/ogimages/tb-devenir-rentier.jpg",
"language": "fr",
"published_at": "2024-05-01T08:05:19.000000Z",
"source": "devenir-rentier.fr",
"relevance_score": null,
"entities": [
{
"symbol": "JNJ",
"name": "Johnson & Johnson",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 20.032438,
"sentiment_score": null,
"highlights": [
{
"highlight": "Mise à jour du portefeuille\n\n\n\n----------------------------------------------------------------------------------------------\n\n\n\nSanté :\n\n\n\n🇫🇷 Sartorius Stedim\n\n🇪🇺 Novo Nordisk\n\n🇺🇸 Abbott Laboratories, <em>Johnson</em> & <em>Johnson</em>\n\n\n\nFinance :\n\n\n\n🇪🇺 Adyen\n\n\n\nIndustrie :\n\n\n\n🇺🇸 Air Product & Chemicals, Lockheed Martin\n\n\n\nTechnologie :\n\n\n\n🇪🇺 ASML Holding",
"sentiment": -0.7783,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "7e12e369-1a00-469d-8b94-a9663121b972",
"title": "die beste Zeit des Jahres ist jetzt!",
"description": "Rückblick auf den Börsenmonat April 2024 und die Entwicklung meines Dividendendepots. Dazu ein Ausblick auf den Mai 2024 und meine anderen Erträge.",
"keywords": "Dividende, Depot, von Dividende leben, monatliches Einkommen mit Aktien, Blog, Dividendenblog, Finanzblog, Finanzblogger, Aktie, Aktien, Dividendenstrategie, Dividendendepot, reich mit Dividenden, Dividenden einsammeln, Dividendensammler, nachhaltige Dividende, nachhaltig sorgenfrei leben, Divantis-Depot, Dividenden Depot aufbauen",
"snippet": "5 ( 17 )\n\nIn meinem Dividendenkalender lässt sich die Verteilung der Dividenden jedes Jahr gut sehen: der Schwerpunkt liegt im Mai, weil dann die meisten deuts...",
"url": "https://www.divantis.de/lasst-die-dividenden-sprudeln-die-beste-zeit-des-jahres-ist-jetzt/",
"image_url": "https://www.divantis.de/wp-content/uploads/2024/05/Kalenderblatt-2024-05-scaled.jpg",
"language": "de",
"published_at": "2024-05-01T06:25:16.000000Z",
"source": "divantis.de",
"relevance_score": null,
"entities": [
{
"symbol": "JNJ",
"name": "Johnson & Johnson",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 9.517048,
"sentiment_score": null,
"highlights": [
{
"highlight": "Dividendenveränderungen\n\nIm April wurden bei meinen Depottiteln folgende Dividendenveränderungen verkündet:\n\nProcter & Gamble: Erhöhung der Quartalsdividende von 0,9407 US$ auf 1,0065 US$ (+7,0%)\n\n<em>Johnson</em> & <em>Johnson</em>: Erhöhung der Quartalsdividende von 1,19 US$ auf 1,24 US$ (+4,2%)\n\nAusblick auf den Mai\n\nMit der zum April-Ultimo ausgezahlten Munich-Re-Dividende",
"sentiment": 0.5707,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "d6025a46-01b3-456b-82ac-3d252e79e757",
"title": "April 2024 Monatsbericht, Österreichische Post, Coca-Cola und Johnson+Johnson erhöht 😎",
"description": "Willkommen im Bergfahrten Blog - das 4. Monat und das 1/3 von 2024 ist bereits vorbei. Es war ein turbulentes Monat mit Reduktion von Depotpositionen und nachkaufen bei langweiligen Qualitätsunternehmen. Das Betriebsvermögen fiel im April auf 789 TEUR, Gold ist gestiegen, Bitcoin seit Herbst 2023 erstmal gefallen und viele Aktien haben sich ausgeglichen 💚 Die…",
"keywords": "",
"snippet": "Willkommen im Bergfahrten Blog – das 4. Monat und das 1/3 von 2024 ist bereits vorbei. Es war ein turbulentes Monat mit Reduktion von Depotpositionen und nach...",
"url": "https://bergfahrten.com/2024/05/01/april-2024-monatsbericht-osterreichische-post-coca-cola-und-johnsonjohnson-erhoht-%f0%9f%98%8e/",
"image_url": "https://bergfahrten.files.wordpress.com/2019/02/image-9.png",
"language": "de",
"published_at": "2024-05-01T06:20:06.000000Z",
"source": "bergfahrten.com",
"relevance_score": null,
"entities": [
{
"symbol": "JNJ",
"name": "Johnson & Johnson",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 87.82486,
"sentiment_score": null,
"highlights": [
{
"highlight": "Das Betriebsvermögen fiel im April auf 789 TEUR, Gold ist gestiegen, Bitcoin seit Herbst 2023 erstmal gefallen und viele Aktien haben sich ausgeglichen 💚\n\nDie größte Veränderung im April war die Einbuchung von Solventum (Spin Off von 3M) und der Nachkauf von der Österreichischen Post, Coca-Cola und <em>Johnson</em> & <em>Johnson</em> 😎\n\nNeuer aktueller Diagramm Stand",
"sentiment": 0.6705,
"highlighted_in": "main_text"
},
{
"highlight": "Post (Ex Dividende für Mai), Munich RE, India Fund, Intel, <em>Johnson</em> & <em>Johnson</em>, 3M (Ex Solventum) und WBA.\n\nUnverändert zeigte sich im Mai VIG, SSE und Reckitt Benckiser.\n\nSteigende Kurse zeigten sich bei Gold, Barry Callebaut, EVN, Novo Nordisk, Coca-Cola, Kimberley-Clark, Procter & Gamble und der Start von Null für die Einbuchung von Solventum.",
"sentiment": 0.6705,
"highlighted_in": "main_text"
},
{
"highlight": "April 2024 Monatsbericht, Österreichische Post, Coca-Cola und <em>Johnson</em>+<em>Johnson</em> erhöht 😎",
"sentiment": 0.6705,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "95603340-822c-4111-9d3a-f512bf347103",
"title": "Covishield side effects: AstraZeneca expresses 'sympathy' for those who lost loved ones",
"description": "Following AstraZeneca's acknowledgment of a rare side effect associated with its COVID-19 vaccine, known as Covishield in India, the UK pharmaceutical giant extended sympathy to those impacted. Reaffirming its dedication to patient safety amidst concerns about potential rare side effects, AstraZeneca emphasised the vaccine's overall safety profile. The company underscored the stringent standards of regulatory authorities to ensure the safe use of medicines, including vaccines. AstraZeneca highlighted the extensive clinical trial data and real-world evidence consistently supporting the safety and efficacy of the vaccine.",
"keywords": "covishield, covishield side effects, clot in blood vessels, AstraZeneca, COVID vaccines, Thrombosis Thrombocytopenia Syndrome, TTS, Serum Institute of India, covishield blod clot, covishield dangers",
"snippet": "You Might Also Like: Covishield Vaccine: Bereaved parents to take Serum Institute of India to Court following AstraZeneca's rare side effect admission\n\n\n\n\n\n(You...",
"url": "https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/covishield-side-effects-astrazeneca-expresses-sympathy-for-those-who-lost-loved-ones/articleshow/109744823.cms",
"image_url": "https://img.etimg.com/thumb/msid-109745320,width-1200,height-630,imgsize-11860,overlay-economictimes/photo.jpg",
"language": "en",
"published_at": "2024-05-01T04:38:19.000000Z",
"source": "economictimes.indiatimes.com",
"relevance_score": null,
"entities": [
{
"symbol": "JNJ",
"name": "Johnson & Johnson",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 16.964485,
"sentiment_score": -0.296,
"highlights": [
{
"highlight": "Notably in 2023, the World Health Organisation (WHO) said in its report that TTS emerged as a new adverse event following immunisation in individuals vaccinated with COVID-19 non-replicant adenovirus vector-based vaccines.This sentence refers to the AstraZeneca COVID-19 ChAdOx-1 vaccine and the <em>Johnson</em> & <em>Johnson</em> Janssen COVID-19 Ad26.COV2-S vaccines",
"sentiment": -0.296,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "29d84685-5aa5-418c-8a6a-2012151f214c",
"title": "Berkshire after Buffett: can any stockpicker follow the Oracle?",
"description": "Ted Weschler and Todd Combs stand to take over a $354bn portfolio from the world’s best-known investor",
"keywords": "",
"snippet": "Print this page\n\nWarren Buffett’s deputies are trailing both the legendary investor and the S&P 500 index, according to a Financial Times analysis that examin...",
"url": "https://www.ft.com/content/fd3b3324-d775-4e09-a916-76f2f3ac675b",
"image_url": "https://www.ft.com/__origami/service/image/v2/images/raw/https%3A%2F%2Fwww.ft.com%2F__origami%2Fservice%2Fimage%2Fv2%2Fimages%2Fraw%2Fhttps%253A%252F%252Fd1e00ek4ebabms.cloudfront.net%252Fproduction%252F94f4fdc2-a875-4703-beac-45345e6a6135.jpg%3Fsource%3Dnext-article%26fit%3Dscale-down%26quality%3Dhighest%26width%3D700%26dpr%3D1?source=next-opengraph&fit=scale-down&width=900",
"language": "en",
"published_at": "2024-05-01T04:00:14.000000Z",
"source": "ft.com",
"relevance_score": null,
"entities": [
{
"symbol": "JNJ",
"name": "Johnson & Johnson",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 5.903847,
"sentiment_score": 0.24695,
"highlights": [
{
"highlight": "Electric Q1/14-Q1/17 8.12 -0.03 Buffett General Motors Q1/14 -Q2/23 5.63 3.3 Combs/Weschler Globe Life Q1/14-Q3/23 153.7 0.36 Buffett Goldman Sachs Q1/14 -Q1/20 23.28 0.18 Buffett Graham Holdings Q1/14-Q4/17 47.56 0.16 Buffett HP Q1/22-Q4/23 -11.93 -0.45 Buffett IBM Q1/14-Q4/17 -5.76 -1.04 Buffett Jefferies Financial Q3/22-Q4/23 51.08 0.05 Combs/Weschler <em>Johnson</em>",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "& <em>Johnson</em> Q1/14-Q2/23 121.44 0.03 Buffett JPMorgan Chase Q3/18-Q3/20 21.21 -0.36 Buffett Kinder Morgan Q4/15-Q3/16 42.67 1.19 Combs/Weschler Kraft Foods Q1/14-Q2/15 102.69 0.01 Buffett Kraft Heinz Q3/15-Q4/23 -25.28 -2.71 Buffett Kroger Q4/19-Q4/23 71.59 7.54 Combs/Weschler Lee Enterprises Q1/14 -Q3/16 -16.43 0 Combs/Weschler Lennar Q2/23-Q4/23 2.12",
"sentiment": 0.4939,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "428ef10d-0f22-4118-ac16-3aa659e6065a",
"title": "A look at the divestment demands by McGill University protesters",
"description": "MONTREAL — Pro-Palestinian activists have set up protest camps at McGill and a small number of other Canadian universities, following a wave of action seen at…",
"keywords": "",
"snippet": "This advertisement has not loaded yet, but your article continues below.\n\nA look at the divestment demands by McGill University protesters\n\nArticle content MONT...",
"url": "https://financialpost.com/pmn/business-pmn/a-look-at-the-divestment-demands-by-mcgill-university-protesters",
"image_url": "https://dcs-static.gprod.postmedia.digital/16.0.2/websites/images/fp/favicon-fp.ico",
"language": "en",
"published_at": "2024-04-30T19:09:13.000000Z",
"source": "financialpost.com",
"relevance_score": null,
"entities": [
{
"symbol": "JNJ",
"name": "Johnson & Johnson",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 13.073427,
"sentiment_score": -0.6079,
"highlights": [
{
"highlight": "Article content It also includes several big Canadian banks, targeted because of their apparent holdings in weapons manufacturers; Canadian grocers that sell Israeli products; and companies that have expanded into the country, or plan to, including Shake Shack, Open Text Corp. and <em>Johnson</em> & <em>Johnson</em>. What kind of financial significance is there?",
"sentiment": -0.6079,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "0308a692-2934-488e-8980-64e1c73fdb47",
"title": "Spotlight on Johnson & Johnson: Analyzing the Surge in Options Activity - Johnson & Johnson (NYSE:JNJ)",
"description": "",
"keywords": "",
"snippet": "Loading... Loading...\n\nInvestors with a lot of money to spend have taken a bearish stance on Johnson & Johnson JNJ.\n\nAnd retail traders should know.\n\nWe noticed...",
"url": "https://www.benzinga.com/insights/options/24/04/38531452/spotlight-on-johnson-johnson-analyzing-the-surge-in-options-activity",
"image_url": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
"language": "en",
"published_at": "2024-04-30T18:46:29.000000Z",
"source": "benzinga.com",
"relevance_score": null,
"entities": [
{
"symbol": "JNJ",
"name": "Johnson & Johnson",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 146.52621,
"sentiment_score": 0.179227,
"highlights": [
{
"highlight": "Investors with a lot of money to spend have taken a bearish stance on <em>Johnson</em> & <em>Johnson</em> JNJ.\n\nAnd retail traders should know.\n\nWe noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.\n\nWhether this is an institution or just a wealthy individual, we don't know.",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "Today, Benzinga's options scanner spotted 8 options trades for <em>Johnson</em> & <em>Johnson</em>.\n\nThis isn't normal.\n\nThe overall sentiment of these big-money traders is split between 25% bullish and 62%, bearish.\n\nOut of all of the options we uncovered, 7 are puts, for a total amount of $452,590, and there was 1 call, for a total amount of $33,460.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $145.0 to $155.0 for <em>Johnson</em> & <em>Johnson</em> over the recent three months.\n\nVolume & Open Interest Development\n\nAssessing the volume and open interest is a strategic step in options trading.",
"sentiment": 0.7783,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Johnson</em> & <em>Johnson</em> 30-Day Option Volume & Interest Snapshot\n\nBiggest Options Spotted:\n\nSymbol PUT/CALL Trade Type Sentiment Exp.",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "BEARISH 10/18/24 $5.95 $5.8 $5.95 $145.00 $119.0K 805 707 JNJ PUT TRADE NEUTRAL 10/18/24 $5.95 $5.8 $5.88 $145.00 $117.6K 805 507 JNJ PUT TRADE BEARISH 10/18/24 $5.95 $5.8 $5.92 $145.00 $59.2K 805 307 JNJ PUT TRADE BULLISH 10/18/24 $6.0 $5.95 $5.95 $145.00 $47.6K 805 127 JNJ PUT TRADE BEARISH 10/18/24 $5.8 $5.6 $5.76 $145.00 $40.3K 805 779\n\nAbout <em>Johnson</em>",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "& <em>Johnson</em>\n\n<em>Johnson</em> & <em>Johnson</em> is the world's largest and most diverse healthcare firm.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Current Position of <em>Johnson</em> & <em>Johnson</em>\n\nWith a volume of 4,066,464, the price of JNJ is down -1.09% at $145.22.\n\nRSI indicators hint that the underlying stock may be oversold.\n\nNext earnings are expected to be released in 79 days.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "What The Experts Say On <em>Johnson</em> & <em>Johnson</em>\n\n5 market experts have recently issued ratings for this stock, with a consensus target price of $179.4.\n\nAn analyst from B of A Securities has decided to maintain their Neutral rating on <em>Johnson</em> & <em>Johnson</em>, which currently sits at a price target of $170.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on <em>Johnson</em> & <em>Johnson</em> with a target price of $175.\n\nAn analyst from HSBC upgraded its action to Buy with a price target of $170.\n\nAn analyst from Morgan Stanley persists with their Equal-Weight rating on <em>Johnson</em> & <em>Johnson</em>, maintaining a target price of $167.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "If you want to stay updated on the latest options trades for <em>Johnson</em> & <em>Johnson</em>, Benzinga Pro gives you real-time options trades alerts.",
"sentiment": 0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "Spotlight on <em>Johnson</em> & <em>Johnson</em>: Analyzing the Surge in Options Activity - <em>Johnson</em> & <em>Johnson</em> (<em>NYSE:JNJ</em>)",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "916a5519-4506-4459-852c-c18f6d30f7f6",
"title": "Stifel, Morgan Stanley bullish on newly public Contineum (NASDAQ:CTNM)",
"description": "Stifel started coverage of newly public Contineum Therapeutics (CTNM) with a buy rating, while Morgan Stanley initiated coverage with an overweight rating. Read more here.",
"keywords": "",
"snippet": "Stifel initiated coverage of Contineum Therapeutics (NASDAQ:CTNM) with a buy rating, citing the company’s drug candidate PIPE-791 for the treatment of idiopat...",
"url": "https://seekingalpha.com/news/4096594-stifel-morgan-stanley-bullish-on-newly-public-contineum",
"image_url": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1973843947/image_1973843947.jpg?io=getty-c-w750",
"language": "en",
"published_at": "2024-04-30T17:10:58.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "JNJ",
"name": "Johnson & Johnson",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 28.257143,
"sentiment_score": -0.7783,
"highlights": [
{
"highlight": "Stifel also noted that the company’s drug candidates for major depressive disorder, which is partnered with <em>Johnson</em> & <em>Johnson</em> (JNJ), and multiple sclerosis offer “compelling optionality.”\n\nStifel set its price target for the stock at $29.\n\nMorgan Stanley also initiated coverage of the stock, rating it overweight with a price target of $25.",
"sentiment": -0.7783,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "JNJ",
"total_documents": 14,
"sentiment_avg": -0.0025687038898468016
}
]
}
Other details
Exchange
- New York Stock Exchange
- equity
- Healthcare
- us